Plain-English translation of NCT07200102 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called as a maintenance treatment for patients with multiple myeloma who have just received CAR-T cell therapy. CAR-T therapy is a powerful cancer treatment that uses your own immune cells to fight myeloma, but the effects don't always last permanently. The researchers believe that , given as follow-up treatment, might work together with the CAR-T cells to keep myeloma under control for longer.
After CAR-T cell therapy, many patients with aggressive myeloma eventually experience relapse. Right now, there is no standard medication given after CAR-T to help prevent this. This trial is testing whether this medication could improve long-term outcomes by working alongside the CAR-T cells to eliminate any remaining cancer cells.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will start taking the medication about 30 to 60 days after your CAR-T infusion, depending on your disease status. You will receive weekly doses of the medication for up to 12 months (12 treatment cycles), with each cycle lasting 28 days. During this time, you'll have regular clinic visits for blood tests and disease monitoring to see how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States